Pharmaceutical

Elite Pharmaceuticals (OTCBB:ELTP) today reported positive topline results from a pilot study conducted for SequestOx™, Elite’s immediate release Oxycodone Hydrochloride product that incorporates its proprietary abuse-deterrent technology. As quoted in the press release: IMS reports approximately $400 million annually in revenue for the immediate release oxycodone generic market. There is currently one other approved, but …

Elite Pharmaceuticals (OTCBB:ELTP) today reported positive topline results from a pilot study conducted for SequestOx™, Elite’s immediate release Oxycodone Hydrochloride product that incorporates its proprietary abuse-deterrent technology.
As quoted in the press release:

IMS reports approximately $400 million annually in revenue for the immediate release oxycodone generic market. There is currently one other approved, but not yet commercialized, abuse-deterrent product and many non-abuse deterrent generic products in this market. Immediate release oxycodone is one of the most highly abused opioids in the U.S.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20181.92+80.54
TSXV705.58+14.41
DOW31253.13-236.94
S&P 5003900.79-22.89
NASD11388.50-29.66
ASX7064.50-118.20

COMMODITIES

Commodities
Gold1840.78-1.41
Silver21.87-0.03
Copper4.27-0.01
Palladium2016.82+12.81
Platinum963.00+4.00
Oil111.55-0.66
Heating Oil3.65-0.01
Natural Gas8.05-0.26

DOWNLOAD FREE REPORTS

×